Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2026 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.960-1.060 for the period, compared to the consensus earnings per share estimate of 0.970. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

Amneal Pharmaceuticals Trading Down 1.0%

AMRX opened at $18.32 on Friday. The company has a fifty day moving average price of $16.23 and a two-hundred day moving average price of $14.26. Amneal Pharmaceuticals has a 1-year low of $7.66 and a 1-year high of $19.26. The company has a market cap of $5.84 billion, a P/E ratio of 37.39 and a beta of 1.26. The company has a current ratio of 2.20, a quick ratio of 1.59 and a debt-to-equity ratio of 77.65.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The business had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. Analysts predict that Amneal Pharmaceuticals will post 0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on AMRX. The Goldman Sachs Group restated a “buy” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a research note on Friday. Barclays raised their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Weiss Ratings raised Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Finally, UBS Group raised their price objective on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

Insider Buying and Selling

In other news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director owned 93,660 shares in the company, valued at $1,211,960.40. This trade represents a 27.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 17.30% of the company’s stock.

Key Amneal Pharmaceuticals News

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q2 results exceeded expectations. Amneal reported revenue of approximately $796 million, GAAP net income of $58 million, adjusted EBITDA of $206 million and adjusted diluted EPS of $0.30, above the $0.24 analyst consensus and up from $0.25 a year earlier. Amneal Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects 2026 revenue of $3.1 billion to $3.2 billion, compared with a prior outlook near $3.1 billion, suggesting continued confidence in demand and operating performance. AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
• Positive Sentiment: Debt repricing should reduce interest expense. The company completed a July debt repricing, which is expected to lower borrowing costs and support future earnings and cash flow. Amneal Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: EPS guidance was broadly in line with consensus. Amneal forecast 2026 EPS of $0.96 to $1.06 versus the $0.97 consensus estimate. While the midpoint is slightly above expectations, the range does not represent a major upward revision.
• Negative Sentiment: Investors may be taking profits after the earnings-driven rally. The strong quarterly beat and revenue outlook improvement were likely already reflected in the stock after its recent advance, leaving limited upside when full-year earnings guidance was only modestly better than expectations. Amneal beats expectations in strong Q2 2026

Institutional Investors Weigh In On Amneal Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP grew its position in shares of Amneal Pharmaceuticals by 5.3% in the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock valued at $123,473,000 after purchasing an additional 624,609 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Amneal Pharmaceuticals by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,609,040 shares of the company’s stock worth $70,681,000 after buying an additional 177,906 shares in the last quarter. Morgan Stanley grew its stake in Amneal Pharmaceuticals by 37.5% during the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after acquiring an additional 1,315,018 shares in the last quarter. Nantahala Capital Management LLC grew its position in shares of Amneal Pharmaceuticals by 14.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after purchasing an additional 558,877 shares in the last quarter. Finally, State Street Corp grew its position in Amneal Pharmaceuticals by 3.4% during the fourth quarter. State Street Corp now owns 4,110,410 shares of the company’s stock worth $51,791,000 after buying an additional 136,662 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.